C. Andrew Kistler, MD, PharmD, RPh

Andy authors Cancer Therapy Advisor's "In the Clinic" column. He is a Gastroenterology and Hepatology Fellow at Thomas Jefferson University Hospital in Philadelphia, PA.

Most Recent Articles by C. Andrew Kistler, MD, PharmD, RPh

Renal Cell Carcinoma:  How Biomarkers Could Affect Drug Development

Renal Cell Carcinoma: How Biomarkers Could Affect Drug Development

By

An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).

Pancreatic Cancer and the Microbiome — In the Clinic

Pancreatic Cancer and the Microbiome — In the Clinic

By

In the future, targets of drug development may be within the microbiome.

Brentuximab in Classical Hodgkin Lymphoma — In the Clinic

Brentuximab in Classical Hodgkin Lymphoma — In the Clinic

By

Brentuximab vedotin is an anti-CD30 monoclonal antibody that targets the Reed-Sternberg cells found in patients with classical HL.

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

By

Colonic stenting can be used as a temporizing measure to help bridge the patient to surgery for optimal timing.

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

By

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

More Articles by C. Andrew Kistler, MD, PharmD, RPh

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs